Observation of a Possible Successful Treatment of DEPDC5-Related Epilepsy with mTOR Inhibitor
Open Access
- 1 June 2023
- journal article
- research article
- Published by Georg Thieme Verlag KG in Neuropediatrics
- Vol. 54 (05) , 344-346
Abstract
The mechanistic target of the rapamycin signaling pathway serves as a central regulator of cell metabolism, growth, proliferation, and survival. In its regulation, the GTPase-activating protein activity toward Rags1 complex has an inhibitory effect. Mutations in genes encoding this complex protein are among the most common abnormalities in focal epilepsies. Within these mutations, the mutations affecting the DEPDC5 gene have been associated with different autosomal dominantly inherited epilepsy types. Due to the limited data available on mTOR inhibitor therapy in nontuberous sclerosis complex epileptic patients, here we present the clinical management of a patient with intractable epilepsy, skin hypopigmentation, and a DEPDC5 variant. The patient's phenotype is compatible with a nonlesional DEPDC5-related epileptic encephalopathy. We initiated compassionate, off-label everolimus treatment as the patient's condition continuously deteriorated. Due to bilateral pneumonia occurring at the beginning of the treatment, it was temporarily discontinued, and resumed in half the dose. Follow-up examination after 18 months showed a 90% reduction in seizure frequency with moderate improvement in attention function and nutritional status. Our case report emphasizes the importance of early genetic testing in patients with epileptic encephalopathy. Clinical consequences of mammalian target of rapamycin complex 1 (mTORC1) upregulation may be amenable to tailored treatment with mTOR inhibitors. A clinical trial on an international scale would be needed to draw conclusions.Keywords
Funding Information
- Medical School of University of Pécs, "ÁOK-KA" Research Program (KA-2021-13)
This publication has 13 references indexed in Scilit:
- GATORopathies: The role of amino acid regulatory gene mutations in epilepsy and cortical malformationsEpilepsia, 2019
- The landscape of epilepsy-related GATOR1 variantsGenetics in Medicine, 2019
- Second-hit mosaic mutation in mTORC1 repressor DEPDC5 causes focal cortical dysplasia–associated epilepsyJournal of Clinical Investigation, 2018
- GATOR1 complex: the common genetic actor in focal epilepsiesJournal of Medical Genetics, 2016
- Toward rapamycin analog (rapalog)-based precision cancer therapyActa Pharmacologica Sinica, 2015
- mTOR inhibition suppresses established epilepsy in a mouse model of cortical dysplasiaEpilepsia, 2015
- Mutations in mammalian target of rapamycin regulator DEPDC5 cause focal epilepsy with brain malformationsAnnals of Neurology, 2014
- Everolimus treatment of refractory epilepsy in tuberous sclerosis complexAnnals of Neurology, 2013
- Rapamycin Prevents Seizures After Depletion of STRADA in a Rare Neurodevelopmental DisorderScience Translational Medicine, 2013
- Biallelic TSC gene inactivation in tuberous sclerosis complexNeurology, 2010